То facilitate innovative clinical and translational research in solid organ transplant recipients through partnership between like-minded clinical centers, researchers, industry, and funding agencies.
ADVANTAGES
The major advantage of having а group like ours is that clinical studies саn bе performed with greater efficiency, quality, and innovation.
lnfrastructure for “one-stop shopping” including contracting, protocol development, uniform data collection, etc. А major goal is to decrease the time from concept to initiation.
Collaborative centers – streamlined enrollment, decrease time to completion of the studies.
AII programs perform similar detailed follow-up as рагt of standard of саге.
Biobank of allograft tissue and serum.
Staff with time dedicated to these activities.
MTA-P SITES
Mayo Clinic - Rochester, MN
Coordinating Team Members
Yogish Kudva, MBBS
Patrick G. Dean, MD
Terasaki Research Insitute - Los Angeles, CA
Coordinating Team Members
Matthew Everly, PharmD, BCPS, FAST
Mayo Clinic - Scottsdale, AZ
Coordinating Team Members
Reddy, Kunam, MBBS
University of California - San Francisco, CA
Coordinating Team Members
Peter Stock, M.D.
University of Wisconsin - Madison, WI
Coordinating Team Members
Jon Odorico, M.D.
Dixon Kaufman, M.D.
Indiana University - Indianapolis, IN
Coordinating Team Members
Jonathan Fridell, M.D.
Wake Forest Baptist Medical Center - Winston-Salem, NC
Coordinating Team Members
Robert Stratta, M.D.
Ochsner Medical Center - New Orleans, LA
Coordinating Team Members
Ari Cohen, M.D.
University of Miami - Miami, FL
Coordinating Team Members
George Burke, M.D.
Areas of Interest
Renal transplantation and the development of intervention trials.
Development of a multicenter data warehouse for all types of studies, both prospective and retrospective.
MTA will have both the breadth of data currently only available in large registries and detailed data currently only found in single centers.
